Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Nicolaus Kröger, Giulia Sbianchi, Tiarlan Sirait, Christine Wolschke, Dietrich Beelen, Jakob Passweg, Marie Robin, Radovan Vrhovac, Grzegorz Helbig, Katja Sockel, Eibhlin Conneally, Marie Thérèse Rubio, Yves Beguin, Jürgen Finke, Paolo Bernasconi, Elena Morozova, Johannes Clausen, Peter von dem Borne, Nicolaas Schaap, Wilfried SchroyensFrancesca Patriarca, Nicola Di Renzo, Zeynep Arzu Yeğin, Patrick Hayden, Donal McLornan, Ibrahim Yakoub-Agha

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT'. Together they form a unique fingerprint.

Medicine & Life Sciences